Drug intelligence / Profile preview

envafolimab + S-1

Development stage: Unknown
Lead developer: 3D Medicines
Modality: Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous, Oral

Overview

Envafolimab + S-1 is a combination therapy consisting of envafolimab, a novel recombinant humanized single-domain PD-L1 antibody formulated for subcutaneous injection, and S-1, an oral fluoropyrimidine anticancer agent. This combination is being investigated for the treatment of various advanced solid tumors, particularly pancreatic ductal adenocarcinoma and gastric cancer. The combination has shown promising efficacy with manageable safety profiles in early clinical trials.

Targets

CD274 (Programmed cell death protein 1 ligand 1)TS (Thymidylate synthase)

Beyond the preview

Go deeper on envafolimab + S-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on envafolimab + S-1.

Explore the full profile